文献速递白血病

欧洲停用酪氨酸激酶抑制剂试验(EURO-SKI)在慢性髓性白血病中的最终分析及无治疗缓解的新预后因素

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
PubMed 文献 · J Clin Oncol · 2024-03-12

EURO-SKI 是规模最大的酪氨酸激酶抑制剂(TKI)停药试验,纳入728例处于稳定深度分子学缓解的慢性髓性白血病患者。6个月时434例(61%;95% CI,57至64)维持主要分子学反应(MMR),36个月时678例中309例(46%;95% CI,42至49)维持MMR。TKI治疗时长和停药前深度分子学缓解时长被证实为6个月MMR丢失的显著预测因素,BCR::ABL1转录本类型也被确定为预后因素;6个月后晚期MMR丢失的多因素分析中,TKI治疗时长、外周血原始细胞百分比和诊断时血小板计数为显著因素;36个月全研究期的多重逻辑回归模型证实治疗时长、原始细胞和转录本类型为MMR维持的独立因素。

要点

  • 728例稳定深度分子学缓解的慢性髓性白血病患者停用TKI后,6个月时61%(95% CI,57至64)维持MMR
  • 36个月时678例中46%(95% CI,42至49)维持MMR
  • TKI治疗时长、停药前深度分子学缓解时长、BCR::ABL1转录本类型、外周血原始细胞百分比和诊断时血小板计数与MMR维持相关

核心结论

  • 除治疗时长外,BCR::ABL1转录本类型及诊断时外周血原始细胞应被视为预测无治疗缓解的重要因素。

研究设计与样本

  • 欧洲停用激酶抑制剂(EURO-SKI)研究是规模最大的TKI停药临床试验,纳入728例处于稳定深度分子学缓解的慢性髓性白血病患者。

主要发现

  • 728例患者中,434例(61%;95% CI,57至64)在6个月时维持主要分子学反应(MMR)。
  • 678例患者中,309例(46%;95% CI,42至49)在36个月时维持MMR。
  • TKI治疗时长和停药前深度分子学缓解时长被证实为6个月MMR丢失的显著预测因素。
  • BCR::ABL1转录本类型被确定为预后因素。
  • 对于6个月后晚期MMR丢失,多因素分析中TKI治疗时长、外周血原始细胞百分比和诊断时血小板计数为显著因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mahon FX, Pfirrmann M, Dulucq S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024. PMID: 38471049. doi:10.1200/JCO.23.01647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。